Key Developments: Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

57.78USD
26 Dec 2014
Price Change (% chg)

$0.32 (+0.56%)
Prev Close
$57.46
Open
$57.68
Day's High
$58.01
Day's Low
$57.59
Volume
1,161,351
Avg. Vol
2,933,923
52-wk High
$62.20
52-wk Low
$49.31

Search Stocks

Latest Key Developments (Source: Significant Developments)

SANTEN PHARMACEUTICAL CO LTD completes to acquire ophthalmology assets from Merck & Co., Inc. (second time)
Thursday, 2 Oct 2014 03:00am EDT 

SANTEN PHARMACEUTICAL CO LTD:Completed to acquire ophthalmology assets from Merck & Co., Inc. (second time) with amount of 5.3 billion yen on Oct. 1.Plan disclosed on May 13 and the acquisition of first time was on July 2.  Full Article

Merck & Co Inc completes sale of consumer care business to Bayer AG for $14.2 bln
Wednesday, 1 Oct 2014 11:30am EDT 

Merck & Co Inc:Completes previously announced sale of the Merck Consumer Care (MCC) business to Bayer AG.Effective Oct. 01, Bayer will acquire Merck's existing over-the-counter business, including the global trademark and prescription rights for CLARITIN and AFRIN, for $14.2 bln or about $9 bln.  Full Article

Merck & Co Inc announces first presentation of data on investigational use of keytruda (pembrolizumab) in patients with advanced gastric cancer
Sunday, 28 Sep 2014 03:15am EDT 

Merck & Co Inc:Announced first presentation of data on investigational use of KEYTRUDA (pembrolizumab) - the company's anti-PD-1 therapy - in PD-L1 positive, advanced gastric cancer.Early findings presented showed an overall response rate (confirmed and unconfirmed) of 31 pct. with KEYTRUDA as monotherapy, as measured by investigator assessed, RECIST v1.1 (n= 12/39: 95 pct. CI, 17-47).Similar overall response rates were observed in Asian patients (population with high incidence of gastric cancer) and non-Asian patients.At time of analysis, response durations ranged from 8+ to 20+ weeks with 11 of 12 responders continuing on therapy.  Full Article

Merck & Co Inc to acquire Sigma-Aldrich to enhance position in attractive life science industry
Monday, 22 Sep 2014 06:28am EDT 

Merck & Co Inc and Sigma-Aldrich:Enters into definitive agreement under which Merck will acquire Sigma-Aldrich for $17.0 billion.Merck will acquire all of outstanding shares of Sigma-Aldrich for $140 per share in cash.Says agreed price represents a 37 pct premium to latest closing price of $102.37 on Sept. 19 and 36 pct premium to one-month average closing price.Closing is expected in mid-year 2015.Guggenheim Securities and J.P. Morgan are acting as financial advisers to Merck.Skadden, Arps, Slate, Meagher & Flom LLP is acting as legal adviser to Merck.Morgan Stanley & Co. LLC is acting as financial adviser to Sigma-Aldrich and Sidley Austin LLP is acting as legal adviser.  Full Article

Sun Pharmaceutical Industries Ltd and Merck & Co. Inc. enter into licensing agreement for Tildrakizumab
Wednesday, 17 Sep 2014 08:30am EDT 

Sun Pharmaceutical Industries Ltd and Merck & Co. Inc:Says through their respective subsidiaries, announced an exclusive worldwide licensing agreement for Merck's investigational therapeutic antibody candidate, tildrakizumab.Under terms, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of US$80 mln.Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma.Transaction is subject to customary closing conditions, including the requirements under the Hart Scott-Rodino Antitrust Improvements Act.  Full Article

Merck & Co Inc receives accelerated approval of Keytruda (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy
Thursday, 4 Sep 2014 03:15pm EDT 

Merck & Co Inc:Announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA(pembrolizumab) at a dose of 2 mg/kg every three weeks.For the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.This indication is approved under accelerated approval based on tumor response rate and durability of response.An improvement in survival or disease-related symptoms has not yet been established.Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.KEYTRUDA is the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States and received FDA's Breakthrough Therapy designation for advanced melanoma, which was granted based on the significance of early study findings and the unmet medical need.  Full Article

FDA approves Merck & Co Inc's BELSOMRA (suvorexant) for the treatment of insomnia
Wednesday, 13 Aug 2014 04:49pm EDT 

Merck & Co Inc:Announced that the U.S. Food and Drug Administration (FDA) has approved BELSOMRA (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep.BELSOMRA (pronounced bell-SOM-rah) is a selective antagonist for orexin receptors.Orexin is a neurotransmitter found in a specific part of the brain that can help keep a person awake.FDA has recommended BELSOMRA be classified by the U.S. Drug Enforcement Administration (DEA) as a scheduled product.  Full Article

Merck & Co Inc completes tender offer to acquire Idenix Pharmaceuticals Inc
Tuesday, 5 Aug 2014 06:00am EDT 

Merck & Co Inc:Completion of tender offer for all of outstanding shares of common stock of Idenix Pharmaceuticals Inc. at purchase price of $24.50 per share.As of tender offer representing about 82.5 pct of outstanding common stock of Idenix on fully diluted basis.All of such shares have been accepted for payment in accordance with the terms of tender offer, and Merck expects to promptly pay for all such shares.Following consummation of tender offer, Merck expects to complete acquisition of Idenix later through merger of Merck's wholly-owned subsidiary with and into Idenix without stockholder approval.  Full Article

Merck & Co Inc reaffirms FY 2014 revenue guidance; raises low end of prior FY 2014 EPS guidance to a range in line with analysts' estimates
Tuesday, 29 Jul 2014 06:56am EDT 

Merck & Co Inc:Expects FY 2014 non-GAAP EPS to be between $3.43 and $3.53, which excludes the potential impact of a Venezuelan Bolivar devaluation that was previously included in the range.Expects FY 2014 GAAP EPS to be between $4.44 and $4.77.Continues to expect FY 2014 revenues to be between $42.4 billion and $43.2 billion.FY 2014 EPS of $3.48 and revenue of $42.6 bln - Thomson Reuters I/B/E/S.  Full Article

Merck initiates phase 3 study of Letermovir
Thursday, 24 Jul 2014 08:30am EDT 

Merck Inc:Announces that the first patient has been enrolled in a global Phase 3 clinical study of letermovir (MK-8228), an investigational antiviral agent.Multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of letermovir for the prevention of clinically-significant cytomegalovirus (CMV) infection in adult CMV-seropositive recipients of allogeneic hematopoietic stem cell transplants.  Full Article

CORRECTED-Connections between drug makers and educators abound

(Corrects second paragraph to say "scholarships funded by Merck, Zoetis, Cargill and others this year.")

Search Stocks